Glucose Intravenous Infusion B.P. Bieffe (Glucose)

Glucose Intravenous Infusion B.P. Bieffe is used when rapid glucose delivery is required in a controlled clinical environment.

• Treatment of hypoglycemia in patients unable to take oral glucose.
• Component of parenteral nutrition regimens for patients lacking enteral intake.
• Fluid and electrolyte replacement when combined with appropriate electrolytes.
• Support during perioperative periods to maintain blood glucose levels.
• Management of metabolic disorders that cause low plasma glucose.

Glucose infusion may be associated with a range of observed effects, most of which are related to the metabolic and osmotic properties of the solution.

Common

• Transient elevation of blood glucose levels.
• Local irritation or discomfort at the infusion site.
• Mild nausea or gastrointestinal upset.
• Fluid overload if administered in excessive volume.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Electrolyte imbalances such as hyponatremia or hypokalemia.
• Hypersensitivity or allergic reactions.
• Hyperosmolar coma, a rare but critical condition.

When prescribing Glucose Intravenous Infusion B.P. Bieffe, clinicians should consider several safety factors to minimize risk.

• Verify the patient’s baseline blood glucose level before initiation.
• Adjust infusion rate in individuals with renal or cardiac insufficiency.
• Monitor serum electrolytes, especially sodium and potassium, throughout therapy.
• Avoid use in patients with known hypersensitivity to glucose solutions.
• Use caution in neonates and infants due to immature metabolic pathways.
• Maintain strict aseptic technique to prevent catheter‑related infections.

Glucose infusion can interact with other medications or clinical conditions, influencing efficacy or safety.

Avoid

• Concurrent high‑dose insulin therapy without close glucose monitoring.
• Co‑administration with hypertonic saline solutions that may exacerbate hyperosmolar states.

Use with caution

• Diuretics that affect fluid balance.
• Corticosteroids that increase endogenous glucose production.
• Beta‑adrenergic agonists that raise blood glucose levels.
• Medications that prolong the QT interval when electrolyte shifts occur.